Key recent studies have shown that JQ1 treatment in melanoma and multiple myeloma cells depletes BRD2 and BRD4 from promoter and enhancer regions of the genome, and this was associated with the disruption of transcriptional programs in these cells (43, 44). The gene discussed is BRD2; the disease is AL amyloidosis.